Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rigel (RIGL)
NASDAQ:RIGL
Rigel (RIGL) Stock Price & Analysis
1,385 Followers
RIGL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.12 - $17.29
Previous Close$9.66
Volume58.36K
Average Volume (3M)199.17K
Market Cap
$169.61M
Enterprise Value$173.26M
Total Cash (Recent Filing)$56.93M
Total Debt (Recent Filing)$60.58M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Jul 30, 2024EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding175,406,146
10 Day Avg. Volume1,445,916
30 Day Avg. Volume199,174
Standard Deviation0.24
R-Squared0.05
Alpha-0.00317
Financial Highlights & Ratios
Price to Book (P/B)-3.92
Price to Sales (P/S)1.43
Price to Cash Flow (P/CF)-6.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.48
Enterprise Value/Gross Profit1.58
Enterprise Value/Ebitda-12.49
Forecast
1Y Price Target
$70.00Price Target Upside624.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Rigel News
PremiumCompany Announcements
Rigel Pharmaceuticals’ Strategic Resolutions at 2024 Annual MeetingBulls Say, Bears Say
Bulls Say
Collaborations And PartnershipsThe recent collaborations are expected to test Rezlidhia in additional IDH1-mutant cancers, potentially driving future revenue growth.
Financial PerformanceRigel announced 4Q23 and 2023 full year financial results, posting EPS of $0.00 and ($0.14), respectively, exceeding analysts’ estimates.
Product SalesSales of Rezlidhia for IDH1m r/r AML increased by ~29% QoQ to $4.9M, which was above the analyst's expectations.
Bears Say
EarningsRigel posted EPS of ($0.05) compared to the estimate of ($0.03).
Product SalesTavalisse sales in ITP decreased by 18% QoQ to $21.1M, falling below the estimate.
RevenueRevenue for the quarter was $29.5 million, below the estimate of $31.68 million.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RIGL FAQ
What was Rigel’s price range in the past 12 months?
Rigel lowest stock price was $7.12 and its highest was $17.29 in the past 12 months.
What is Rigel’s market cap?
Currently, no data Available
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is Jul 30, 2024 which is in 8 days.
How were Rigel’s earnings last quarter?
Rigel released its earnings results on May 07, 2024. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.288 by -$0.212.
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate is -$0.29.
How many shares outstanding does Rigel have?
Rigel has 17,558,294 shares outstanding.
What happened to Rigel’s price movement after its last earnings report?
Rigel reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.288. Following the earnings report the stock price went down -16.639%.
Which hedge fund is a major shareholder of Rigel?
Among the largest hedge funds holding Rigel’s share is Graham Capital Management, L.P.. It holds Rigel’s shares valued at 54K.
---
Rigel Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$70.00 (624.64% Upside)
$70.00 (624.64% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 267.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.35%
Trailing 12-Months
Company Description
Rigel
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
---
RIGL Company Deck
---
RIGL Earnings Call
Q1 2024
0:00 / 0:00
---
RIGL Stock 12 Month Forecast
Average Price Target
$70.00
▲(624.64% Upside)
Technical Analysis
Axsome Therapeutics
―
Karyopharm Therapeutics
―
TG Therapeutics
―
Viking Therapeutics
―
Best Analysts Covering RIGL
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-14.35%
reiterated a buy rating 28 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -14.35% per trade.
---